Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Researchers find way to overcome Zika vaccine–Dengue virus conundrum

Researchers have developed a vaccine that provides protection against the Zika virus in mice without increasing susceptibility to Dengue virus infection[1].

The two viruses belong to the same family, known as flaviruses, and share genetic and structural similarities, which can lead to a type of immune cross-reactivity called antibody-dependent enhancement of infection (ADE) if a person is infected with both.

This means that prior exposure to Dengue can result in a more severe response to Zika infection and previous attempts to develop Zika vaccines indicated they might increase the risk of Dengue.

In an attempt to overcome this, researchers developed a recombinant vaccine targeting a viral envelope sub-unit specific to the Zika virus.

They showed that in mice the vaccine induced strong antibody and cellular immune responses, with antibody titres indicating that it would confer protection against Zika virus infection. Furthermore, by incubating blood serum samples from vaccinated mice with Dengue fever virus, they showed that there was no detectable ADE.

“All flaviviruses have the envelope protein on the outside part of the virus. It has three domains,” explains lead author Qiang Chen from Arizona State University, Tempe, Arizona. “The domain III has a unique stretch of DNA for the Zika virus, and we exploited this to generate a robust and protective immune response that is unique for Zika.”

The team says the results indicate that their vaccine could confer robust immunity to Zika while potentially being safer than vaccine candidates explored in research so far.

They also say that their approach could help improve the cost-effectiveness of Zika vaccination as they produced and purified their vaccine in large quantities using plant-based expression in the tobacco plant.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203379

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • vaccine being developed in a laboratory

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.